Table 3.
Neoadjuvant study, data demographics summary
| Parameter | n (Average) | % (Range) |
|---|---|---|
| N Total | 34 | |
| Age | (54) | (23–83) |
| Diagnosis (DX) | ||
| Invasive Ductal Carcinoma | 33 | 97.1 |
| Invasive Lobular Carcinoma | 1 | 2.9 |
| Nuclear Grade | ||
| 1 | 2 | 5.9 |
| 2 | 7 | 20.6 |
| 3 | 25 | 73.5 |
| ER Allred Score | ||
| 0–2 (−) | 11 | 32.4 |
| 3–8 (+) | 23 | 67.6 |
| PR Allred Score | ||
| 0–2 (−) | 13 | 38.2 |
| 3–8 (+) | 21 | 61.8 |
| ER/PR Status | ||
| ER+/PR+ | 21 | 61.8 |
| ER+/PR- | 2 | 5.9 |
| ER-/PR+ | 0 | 0 |
| ER-/PR- | 11 | 32.4 |
| HER2 IHC Score | ||
| 0 | *1* | 2.9 |
| 1+ | 0 | 0 |
| 2+ | 10 | 29.4 |
| 3+ | 23 | 67.6 |
| Pathologic Response | ||
| Partial/No Response | 11 | 32.4 |
| Near complete Response | 11 | 32.4 |
| Complete Response (pCR) | 12 | 35.3 |
| Residual Cancer Burden (RCB) Class | ||
| 0 (pCR) | 12 | 35.3 |
| 1 | 11 | 32.4 |
| 2 | 8 | 23.5 |
| 3 | 3 | 8.8 |
N: total sample size, n: subset of total sample size, ER estrogen receptor, PR progesterone receptor, IHC immunohistochemistry, pCR pathologic complete response. *1 patient presented with an IHC score of 0 but was ISH amplified and received HER2 neoadjuvant therapy and was included in the cohort.*